EGFR and non-small cell lung carcinoma: In phase III clinical trials or combined analyses, afatinib was shown to significantly prolong progression-free survival as well as overall survival compared to standardized cytotoxic chemotherapy in patients with advanced NSCLC harboring EGFR-activating mutations, especially exon 19 deletions [11–13].